| 000 | 01903 a2200445 4500 | ||
|---|---|---|---|
| 005 | 20250515114447.0 | ||
| 264 | 0 | _c20090211 | |
| 008 | 200902s 0 0 eng d | ||
| 022 | _a1460-2385 | ||
| 024 | 7 |
_a10.1093/ndt/gfn159 _2doi |
|
| 040 |
_aNLM _beng _cNLM |
||
| 100 | 1 | _aZhu, Shiming | |
| 245 | 0 | 0 |
_aTransforming growth factor-beta1 is associated with kidney damage in patients with essential hypertension: renoprotective effect of ACE inhibitor and/or angiotensin II receptor blocker. _h[electronic resource] |
| 260 |
_bNephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association _cSep 2008 |
||
| 300 |
_a2841-6 p. _bdigital |
||
| 500 | _aPublication Type: Journal Article; Randomized Controlled Trial; Research Support, Non-U.S. Gov't | ||
| 650 | 0 | 4 | _aAdministration, Inhalation |
| 650 | 0 | 4 |
_aAngiotensin II _xblood |
| 650 | 0 | 4 |
_aAngiotensin II Type 1 Receptor Blockers _xpharmacology |
| 650 | 0 | 4 |
_aAngiotensin-Converting Enzyme Inhibitors _xpharmacology |
| 650 | 0 | 4 |
_aBenzazepines _xpharmacology |
| 650 | 0 | 4 | _aDouble-Blind Method |
| 650 | 0 | 4 | _aFemale |
| 650 | 0 | 4 | _aHumans |
| 650 | 0 | 4 |
_aHypertension _xblood |
| 650 | 0 | 4 |
_aKidney _xdrug effects |
| 650 | 0 | 4 |
_aKidney Diseases _xdrug therapy |
| 650 | 0 | 4 | _aMale |
| 650 | 0 | 4 | _aMiddle Aged |
| 650 | 0 | 4 | _aProspective Studies |
| 650 | 0 | 4 |
_aTetrazoles _xpharmacology |
| 650 | 0 | 4 | _aTransforming Growth Factor beta1 |
| 650 | 0 | 4 |
_aValine _xanalogs & derivatives |
| 650 | 0 | 4 | _aValsartan |
| 700 | 1 | _aLiu, Yuying | |
| 700 | 1 | _aWang, Liqi | |
| 700 | 1 | _aMeng, Qing H | |
| 773 | 0 |
_tNephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association _gvol. 23 _gno. 9 _gp. 2841-6 |
|
| 856 | 4 | 0 |
_uhttps://doi.org/10.1093/ndt/gfn159 _zAvailable from publisher's website |
| 999 |
_c17890015 _d17890015 |
||